Adherence to Dihydroartemisinin-Piperaquine Treatment among Patients with Uncomplicated Malaria in Northern Ghana.
Journal
Journal of tropical medicine
ISSN: 1687-9686
Titre abrégé: J Trop Med
Pays: Egypt
ID NLM: 101524194
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
11
2018
revised:
19
01
2019
accepted:
29
01
2019
entrez:
7
5
2019
pubmed:
7
5
2019
medline:
7
5
2019
Statut:
epublish
Résumé
Treatment adherence has been described as the process whereby patients take medications, follow diet, and effect other lifestyle changes that relate to agreed recommendations from healthcare providers. The determinants of such treatment adherence include patient, the health condition, therapy type, socioeconomic conditions, and the healthcare system. The study examined adherence in malaria patients treated with dihydroartemisinin-piperaquine in routine clinical care in northern Ghana. The study was conducted in Navrongo Health Research Centre in the Kassena-Nankana district of northern Ghana. Patients confirmed with uncomplicated malaria were prescribed dihydroartemisinin-piperaquine in blister packs to be taken daily for three days. Follow-up visits were made on days 3 and 28 after diagnosis to collect data on adherence, drug safety and therapeutic effectiveness. During follow-up visits, in-depth interviews were conducted and the blister packs directly observed for the number of tablets remaining. The in-depth interviews documented day-by-day account of doses taken, number of tablets taken during each dose, time of each dose, reasons for any leftover or missed dose, and whether or not there was vomiting. Treatment adherence was classified as definitely nonadherent, incomplete adherence, and completely adherent. A total of 405 patients were screened; 299 were positive by rapid diagnostic testing and 216 by microscopy. The average age was 12 years and females represented 54.0%. All participants completed day 3 follow-up but 12.7% had leftover pills. Treatment adherence was 50.9% (95% CI 44.1, 57.8), 36.1% (95% CI 29.7, 42.9), and 13.0% (95% CI 8.8, 18.2) for completely adherent, incomplete adherence, and definitely nonadherent, respectively. All completely adherent patients were free of parasitemia on day 28 of follow-up. A total of 49 adverse events related to malaria symptoms were documented. Effort to improve adherence should be individualized as it is dependent on a number of factors such as the patients' temperament, the disease, support at home, and complexity of treatment.
Identifiants
pubmed: 31057628
doi: 10.1155/2019/5198010
pmc: PMC6463560
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5198010Références
Arch Dermatol. 2002 Mar;138(3):337-42
pubmed: 11902984
Trop Med Int Health. 2003 Sep;8(9):793-802
pubmed: 12950665
Trop Med Int Health. 2004 Jan;9(1):164-70
pubmed: 14728621
Br J Dermatol. 2005 May;152(5):1015-21
pubmed: 15888162
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
Am J Clin Dermatol. 2006;7(4):231-6
pubmed: 16901183
Trop Med Int Health. 2007 Mar;12(3):382-91
pubmed: 17313510
Malar J. 2007 Jul 27;6:96
pubmed: 17662142
Am J Hosp Pharm. 1991 Sep;48(9):1978-88
pubmed: 1928147
J Gen Intern Med. 2010 Apr;25(4):284-90
pubmed: 20131023
N Engl J Med. 2010 Apr 29;362(17):1553-5
pubmed: 20375400
Mayo Clin Proc. 2011 Apr;86(4):304-14
pubmed: 21389250
Am Heart J. 2011 Sep;162(3):412-24
pubmed: 21884856
Clin Infect Dis. 2011 Oct;53(8):772-9
pubmed: 21921220
Drugs. 2012 May 7;72(7):937-61
pubmed: 22515619
BMC Infect Dis. 2012 Jun 24;12:143
pubmed: 22726955
Int J Epidemiol. 2012 Aug;41(4):968-76
pubmed: 22933645
PLoS One. 2014 Jan 20;9(1):e84555
pubmed: 24465418
Malar Res Treat. 2015;2015:452539
pubmed: 25767736
PLoS One. 2015 Jul 27;10(7):e0134275
pubmed: 26214848
Lancet Infect Dis. 2017 Feb;17(2):184-193
pubmed: 27865890
PLoS One. 2018 Mar 28;13(3):e0193995
pubmed: 29590156
J Dev Econ. 2018 Sep;134:68-95
pubmed: 30177864
Behav Res Ther. 1985;23(2):225-7
pubmed: 3159380
J Am Coll Health Assoc. 1980 Jun;28(6):342-5
pubmed: 7391420